EGM-Guided Ablation: CFE, Ganglia, Rotors… ISHNE 2009 Atul Verma, MD FRCPC Staff Cardiologist, Electrophysiologist Southlake Regional Health Centre Newmarket,

Slides:



Advertisements
Similar presentations
AF ablation with 3D mapping: our technique and results
Advertisements

Substrate Ablation (CAFE) A Promising or Vanishing Technique
{ Cardioversion turns 50 Seth Bilazarian MD Private practice theheart.org.
Ali Alsayegh, MD, FRCPC,FACC Consultant Cardiologist, Consultant Cardiac Electrophysiologist.
Atul Verma, MD FRCPC Cardiology/Electrophysiology Heart Rhythm Program, Division of Cardiology Southlake Regional Health Centre Newmarket, Ontario, Canada.
How to do a Roof Line and Prove Block Dhiraj Gupta Liverpool Heart and Chest Hospital.
Atrial Fibrillation in Patients with Cryptogenic Stroke Gladstone DJ et al. N Engl J Med 2014; 370: Presented by Kris Huston | July 21, 2014.
Optimal Method and Outcomes of Catheter Ablation of Persistent AF: The STAR AF 2 Trial Atul Verma, Jiang Chen-yang, Tim Betts, John Radcliffe, Jian Chen,
Ablation for Paroxysmal Atrial Fibrillation (APAF) Trial Presented at The American College of Cardiology Scientific Session 2006 Presented by Dr. Carlo.
INTERVENTIONAL TREATMENT OF ATRIAL FIBRILLATION St. Mary’s Hospital February – August 2007.
Clinical Title Date Jaret Tyler, MD Clinical Cardiac Electrophysiologist Assistant Professor of Medicine Ohio State’s Heart and Vascular Center Atrial.
Katheterablatie van atriumfibrilleren Waar staan we? Lukas Dekker.
John R Onufer MD FHRS.  Paroxysmal(that which terminates spontaneously) Persistent Sustained > 7 days, or lasting < 7 days but requires pharmacologic.
Amr Kamal, M.D Alexandria Main University Hospital Alexandria- Egypt ECRA 2010.
Audit of ablation procedures for AF Barts and The London.
Late outcomes of the Cox-Maze IV procedure for atrial fibrillation Matthew C. Henn MD, Timothy S. Lancaster MD, Jacob R. Miller MD, Laurie A. Sinn RN,
Atrial Fibrillation Andreas Stein Robert Smith, M.D. August 11, 2003.
Impact of Concomitant Tricuspid Annuloplasty on Tricuspid Regurgitation Right Ventricular Function and Pulmonary Artery Hypertension After Degenerative.
Basic Mechanisms of Atrial Fibrillation Relative to Ablation Osama Diab MD, Cardiology Lecturer of Cardiology, Ain Shams Universitry-Cairo Consultant Electrophysiologist,
C.R.E.D.O. C lopidogrel for the R eduction of E vents D uring O bservation Multicenter Multinational (USA, Canada) Prospective Randomized Double Blind.
Substrate and Trigger Ablation for Reduction of Atrial Fibrillation (STAR AF): a randomized, multicentre, international trial by Atul Verma, Roberto Mantovan,
New targets of AF ablation – CFAE and GPs Helmut Pürerfellner Public Hospital Elisabethinen, Academic Teaching Center Linz, Austria.
Catheter Ablation of Atrial Fibrillation: Who? How? How Good? John D. Day, M.D. Director, Utah Cardiovascular Research Institute Utah Heart Clinic Arrhythmia.
©2012 MFMER | slide-1 New methods and techniques in catheter ablation of atrial fibrillation Yong-Mei Cha, MD Mayo Clinic NCF Shenyang, 2014.
RECIST Overview.
Redo afib ablation John R Onufer MD FHRS
Catheter Ablation of AF Electrogram-based Approach
Asklepios Klink St. Georg, Hamburg
EP Sale’s Training Summary.
SWEDMAF Trial Presented at The Heart Rhythm Society Meeting May 2006 Presented by Dr. Carina Blomstrom-Lundqvist SWEDMAF Trial.
Catheter Ablation of Atrial Fibrillation in the Last 10 Years: Breakthroughs and Advances Dr. Feifan Ouyang Asklepios Klinik St. Georg Hamburg Sept. 19th,
Donghui Yang, Lianjun Gao Department of Cardiology First affiliated hospital of Dalian Medical University Will the endpoint of AF ablation be unified?
A-4 Trial Presented at The Heart Rhythm Society Meeting May 2006 Presented by Dr. Pierre Jais Atrial Fibrillation Ablation vs. Antiarrhythmic Drugs Trial.
Catheter Ablation of AF Electrogram-based Approach Division of Cardiology, Taipei Veterans General Hospital and National Yang-Ming University, Taipei,
The Case for Rate Control: In the Management of Atrial Fibrillation Charles W. Clogston, M.D. Cardiologist CHI St. Vincent Heart Clinic Arkansas April.
Date of download: 7/6/2016 Copyright © The American College of Cardiology. All rights reserved. From: Catheter-induced linear lesions in theleft atrium.
Catheter Ablation of Atrial Fibrillation by Roderick Tung, Eric Buch, and Kalyanam Shivkumar Circulation Volume 126(2): July 10, 2012 Copyright.
Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Comparison of Radiofrequency Catheter Ablation of.
Radiofrequency Ablation as Initial Therapy in Paroxysmal Atrial Fibrillation Jens Cosedis Nielsen, M.D., D.M.Sc., Arne Johannessen, M.D., D.M.Sc., Pekka.
Date of download: 9/19/2016 Copyright © The American College of Cardiology. All rights reserved. From: Atrial Tachycardia After Circumferential Pulmonary.
Everolimus-eluting Bioresorbable Vascular Scaffolds in Patients with Coronary Artery Disease: ABSORB III Trial 2-Year Results Stephen G. Ellis, MD,
RESULTS AND DISCUSSION
ADenosine Vasodilator Independent Stenosis Evaluation II
Thomas A. Csepe, BSc, Brian J. Hansen, BSc, Vadim V. Fedorov, PhD 
Left atrial ablation for atrial fibrillation. A
Circ Arrhythm Electrophysiol
Circ Arrhythm Electrophysiol
AF ablation with 3D mapping: our technique and results
Volume 10, Issue 8, Pages (August 2013)
(p for noninferiority = )
MAGIC-AF Trial design: Patients with persistent atrial fibrillation (AF) and remaining in AF after pulmonary vein isolation alone were randomized to either.
Catheter Ablation for the Cure of Atrial Fibrillation Study
Volume 12, Issue 2, Pages (February 2015)
ΝΟΣΟΣ ΤΑΧΥΒΡΑΔΥΚΑΡΔΙΑΣ: ΕΜΦΥΤΕΥΣΗ ΒΗΜΑΤΟΔΟΤΗ Η ΚΑΤΑΛΥΣΗ ΚΟΛΠΙΚΗΣ ΜΑΡΜΑΡΥΓΗΣ ; ΓΕΩΡΓΙΟΣ ΣΤΑΥΡΟΠΟΥΛΟΣ ΕΠ.Α ΚΑΡΔΙΟΛΟΓΟΣ ΓΝΘ ΙΠΠΟΚΡΑΤΕΙΟ.
Volume 12, Issue 2, Pages (February 2015)
AFACT Trial design: Patients with long-standing atrial fibrillation were randomized to ganglion plexus ablation (n = 117) vs. control (n = 123) on top.
Volume 13, Issue 1, Pages (January 2016)
Junaid A.B. Zaman et al. JACEP 2017;3:
David J Wilber MD Loyola University Chicago
Risk Factor Modification
Approaches to Ablate Persistent in 2019: The Problems with Mapping AF
Stavros Stavrakis et al. JACEP 2015;1:1-13
Andreu Porta-Sánchez, MD, Andrew C. T
Pitfalls of pacemaker detection of ventricular high-rate events
Atrial fibrillation originating from recipient left atrium after an orthotopic heart transplantation  Auroa Badin, MD, Jaret Tyler, MD, FHRS, Steven J.
Volume 14, Issue 4, Pages (April 2017)
Progressive modification of rotors in persistent atrial fibrillation by stepwise linear ablation  Jichao Zhao, PhD, Yan Yao, MD, PhD, Rui Shi, MD, PhD,
Arrhythmogenic triggers associated with an autonomic response from a posteroseptal region after extensive ablation in a patient with long-standing atrial.
Atrial fibrillation resulting from superior vena cava drivers addressed with cryoballoon ablation: Late reconnection at the site of phrenic nerve pacing.
Catheter ablation for the treatment of persistent atrial fibrillation: Maintenance of sinus rhythm with left atrial appendage and coronary sinus isolation.
Presentation transcript:

EGM-Guided Ablation: CFE, Ganglia, Rotors… ISHNE 2009 Atul Verma, MD FRCPC Staff Cardiologist, Electrophysiologist Southlake Regional Health Centre Newmarket, Canada

Disclosures  Consulting fees/honoraria –Biosense Webster, Medtronic, St Jude Medical, Sanofi Aventis, Astra Zeneca, Servier  Speakers bureau –Biosense Webster, Medtronic, St Jude Medical  Research grants –Biosense Webster, Medtronic, St Jude Medical  Equity, Ownership, Salary, Royalties –None

EGM-Guided Ablation  Complex Fractionated Electrograms (CFE)  STAR AF data  Ganglionated Plexi (GP)  Dominant Frequency (DF)

Question #1  Of the following EGM-based targets, which do you feel offer the greatest potential value as a hybrid strategy to PVI? 1.CFE 2.Ganglionated Plexi 3.Dominant Frequency 4.None of the above

Question #2  In which AF patients do you think CFE are most useful to study/ablate? 1.All AF 2.Paroxysmal AF 3.Persistent AF

Question #3  What do you think are the biggest barriers to using CFE ablation for AF (either alone or in combination)? 1.Not a consistent definition of CFE 2.Not a stable target for ablation 3.Not enough data showing its benefit 4.Too much extra procedural time 5.None of the above

Complex Fractionated Electrograms (CFE)

Theory Behind CFEs Konings et al, Circulation 1997 Intraoperative mapping of RA during induced AF Identified 4 types of atrial potentials during AF Fragmented potentials correlated to pivot points where multiple wavelets arc around a region of functional block OR areas of slow conduction

Definition of CFE – Nademanee JACC 2004 (A)atrial electrograms that are Fractionated & composed of two deflections or more and have a perturbation of the baseline with continuous deflections (B) atrial electrograms with a very short cycle length (<120 ms) with or without multiple potentials when compared with the atrial CL from other parts of the atria

Where are the CFE? PVs Roof Septum RA CS

Nademanee, JACC 2004  AFCL increased from: – 172 ± 26 ms to 237 ± 42 ms  AF termination during ablation: – Paroxysmal – 100% (14% required ibutilide) – Chronic – 91% (28% required ibutilide)  76% success rate after 1 procedure  15% became arrhythmia-free after a second procedure  At least 5% of these successful patients remained on AAD

Oral et al, Circulation 2007  Prospective, non-randomized assessment  CFE ablation only – no PV isolation  N=100  Permanent AF patients only

Oral et al, Circulation 2007  Very low acute termination rate of AF during ablation –Only 16% terminated acutely  Long-term success rate of this approach modest –57% AF-free off medications –44% required two procedures –Average of 14 months follow-up

Reproducibility of CFE Results  Results from other centers not consistent  Part of the problem stems from definition and understanding of CFE  Are these targets really spatially and temporally stable?  Is there a consistent way to define CFE?

Haissaguerre et al, Heart Rhythm 2006  “CFE” are dependent on AFCL  The faster the CL, the more likely it is to see “CFE”  Since AFCL can be variable, so to can occurrence of “CFE”  Therefore, “elusive” “transient” target

Haissaguerre et al, Heart Rhythm 2006  Problem: Are these “CFE”?

Automated CFE Mapping  Subjectivity of CFE definition still a major limitation  Automated algorithms are novel tools to standardize CFE definition and mapping  Averages the signal analysis over 4-8 sec, allowing differentiation from transient vs stable CFE sites

Implementation and Deployment of the CFE Mapping Tool (NAVX)  Activation Detection Criteria –Peak-to-peak voltage threshold > Baseline noise floor –Slope threshold Near field vs. far field –Refractory setting Avoid double counting  Map Display Representation –Average interval represented with color scale (ms) 1-8 second evaluation length ~.05 mV ~20 ms ~50 ms Organized Fractionated

Diagnostic Landmarking: NavX System  3D mapping from standard catheters  Points are collected at electrodes and projected onto map surface  Using MultiPoint technology, points may be collected from –A single electrode –A multipolar catheter –All catheters in use MultiPoint DxL mapping of fractionation Image courtesy of Dr Andrea Natale, CCF

Mapping CFE Regions Courtesy of Dr. Koonlawee Nademanee, Los Angeles, CA By annotating the deflections of the local EGM, a mean CL can be calculated – CFE defined as regions with CL < 120 ms.

DxL Map Settings – CFE Mean Recommended Settings Width10-20 ms (avoid far-field) Refractory30-50 ms (avoid double counting) P-P Sensitivity mV (avoid noise) Segment Length4-8 sec Interpolation4-10 mm Internal/External Projection3-6 mm

CFE Stability – Verma et al, Heart Rhythm 2008 CFE maps taken at 0 and 20 minutes. Degree of overlap and consistency of CFE areas studied. CFE definition – regions with local EGM cycle length <120 ms.

CFE Stability – Verma et al, Heart Rhythm 2008 LPV SEPT RPV PW ROFLR When measured at 0 and 20 minutes, proportion of signals within cycle length ranges are stable. Black = ms White = ms Grey = >200 ms

CFE Stability – Verma et al, Heart Rhythm 2008 AB C D * % Range A, r=0.82 Range C, r=0.08Range B, r=0.21 Degree of Overlap 0/20 minCycle Length ms Cycle Length >200 msCycle Length ms

Substrate vs Trigger Ablation for Reducing Atrial Fibrillation A Multicenter, Randomized Trial Principal Investigator: Atul Verma, MD FRCPC Southlake Regional Health Centre, Canada Presented at Heart Rhythm 2009 – Late Breaking Trials

Study Purpose  To compare the efficacy of three AF ablation strategies: –Targeting the triggers of AF via PV isolation (PVI) –Targeting the substrate of AF maintenance via elimination of complex fractionated electrograms (CFE) –A hybrid approach of PVI + CFE ablation  High-burden paroxysmal (65%) and persistent (35%) AF population  Multicenter, randomized trial

PVI Strategy  Wide, circumferential PV antral isolation  Lesions placed >1-2 cm outside of the PV ostia  Endpoint of entrance block of all PV antra as documented by a circular mapping catheter

CFE Strategy - I  Spontaneous or induced AF (must persist >1 min)  Automated CFE mapping algorithm  All CFE regions targeted (CL<120 ms)  Target all CFE regions in LA, then CS, then RA

CFE Strategy - II  Endpoint of elimination of all CFE sites or termination of AF and non-inducibility of AF  If AF did not terminate after all CFE sites ablated, cardioversion allowed  If AF terminated to AT or AFL, this was mapped/ ablated when possible  IV antiarrhythmics not used during ablation

PVI+CFE Strategy  PVI completed first  Then, CFE mapped (spontaneous or induced AF) and ablated  Endpoint of PVI followed by AF termination/ non- inducibility  If AF not terminated after all CFE ablated, cardioversion allowed

Procedural Details - II CFEPVIPVI+CFEp Procedure Time (min) 224 ± ± ± 68NS Mapping Time (min) 39 ± 1829 ± 2141 ± Fluoroscopy Time (min) 56 ± 2858 ± 2760 ± 34NS RF Time (min) 65 ± 3368 ± 4177 ± 45NS

Freedom from AF/AFL/AT (1 procedure) PVI+CFE PVI CFE Freedom from AF/AFL/AT Months Post-Ablation 5.6% on antiarrhythmics, evenly distributed between groups p=0.002

Freedom from AF/AFL/AT (2 procedures) 5.6% on antiarrhythmics, evenly distributed between groups p< p=0.04

Repeat Procedures p=0.008 p=0.07 p=0.21

Paroxysmal/Persistent Subgroups p=0.14 p=0.03

Conclusions  In high burden paroxysmal/persistent AF patients, PVI+CFE is associated with the highest freedom from atrial arrhythmia at one year  PVI+CFE requires fewer repeat procedures compared to either strategy alone  CFE is associated with the highest recurrence rate and highest number of repeat procedures  Benefit of PVI+CFE may be more pronounced in persistent AF

Ganglionated Plexi (GPs)

Ablating Autonomic Inputs  Evidence from Pappone et al that vagal denervation may be an important reason for AF cure by CARTO-guided approach Pappone et al, Circulation 2004

Targeting GP Inputs  Recently, Sherlag et al, JICE 2005 reported improved success rates with ablation of GPs in addition to PV isolation –90% vs 71% success respectively

Sherlag et al, JACC 2005 GP input may be important in creating a substrate for converting PV firing into AF. Correlation between CFE and regions of autonomic input.

Mixed Clinical Results  Scanavacca et al, Circulation 2006 –Vagal reflex-guided GP ablation in paroxysmal AF (n=10) –29% success rate after one procedure  Pokushalov et al, Heart Rhythm 2009 –Vagal reflex-guided GP ablation vs anatomic ablation of GP sites in paroxysmal AF (n=40) –Selective GP ablation success only 43% –Anatomic GP ablation success 77%

Ganglionated Plexi  Persistent AF population is the next big horizon  Will not be adequately addressed by the “one size fits all” approach  New mapping-based targets need to be assessed

Dominant Frequency (DF)

Dominant Frequency  May represent specific rotor sites responsible for AF perpetuation  May be targeted as a lone or combined hybrid strategy

DF Distribution Sanders et al, Circulation 2005 PAROXYSMAL CHRONIC

Atienza et al, Heart Rhythm 2009 Acute reduction in DF in all chambers associated with higher freedom from AF long-term. Ablation of DFmax sites associated with higher freedom from AF (88% vs 30%) Overall success rate 88% parox and 56% persistent

Summary  EGM-guided ablation is a promising avenue for adjuvant ablation in addition to PVI  May be particularly useful in persistent AF population, but also higher-burden paroxysmals  CFE offers the most promising target at present, but need for more refined definitions  GP ablation may overlap a lot with CFE and data still lacking  DF ablation may be promising, particularly in refining CFE sites